Solefinacin
Reading File
Finding Sources
Searching the Web
solifenacin pharmacology mechanism uses side effects
Reading File
Here is a thorough overview of Solifenacin based on authoritative urology textbook content and web sources.
Solifenacin (Solifenacin Succinate)
Brand Name: VESIcare (tablets), VESIcare LS (oral suspension)
Drug Class: Antimuscarinic / Anticholinergic agent (tertiary amine)
Chemical & Pharmacokinetic Profile
Solifenacin succinate (formerly YM905) is a tertiary amine with excellent oral bioavailability (~90% from the GI tract). Key pharmacokinetic features, per Campbell-Walsh-Wein Urology:
| Parameter | Value |
|---|---|
| Bioavailability | ~90% |
| Mean terminal half-life | 45-68 hours |
| Metabolism | Hepatic, via CYP3A4 |
| Protein binding | High |
| Active metabolite | 4R-hydroxy solifenacin (low concentration, minor clinical contribution) |
The long half-life supports once-daily dosing. Co-administration with CYP3A4 inhibitors (e.g., ketoconazole 200 mg) increases Cmax by ~40% and AUC by ~56%, so dose capping is required.
Mechanism of Action
Solifenacin is a competitive muscarinic receptor antagonist. It blocks muscarinic receptors in the bladder detrusor muscle, which are responsible for acetylcholine-mediated involuntary contractions.
- Primary target: M3 receptors (mediates detrusor contraction)
- Also blocks: M2 receptors (modest affinity) - M2 modulates heart rate and smooth muscle relaxation
- Selectivity: Modest M3 > M2 (and M1) selectivity
Effects on the bladder:
- Reduces involuntary detrusor contractions (overactive bladder)
- Increases maximum bladder capacity
- Delays urge to void
- Also has an effect on sensory function - increases the area under the bladder-volume sensation curve
Indications
- Overactive bladder (OAB) - the primary indication
- Urinary urgency
- Urge urinary incontinence
- Urinary frequency (at least 8 micturitions/24 hours)
Dosing
| Form | Dose | Frequency |
|---|---|---|
| Tablet | 5 mg (starting dose) or 10 mg | Once daily |
| Oral suspension (VESIcare LS) | 1 mg/mL | Once daily |
- Starting dose: 5 mg once daily; can be uptitrated to 10 mg if tolerated
- Dose cap at 5 mg in patients on potent CYP3A4 inhibitors, or with severe renal/hepatic impairment
Key Clinical Trial Evidence
Trials referenced in Campbell-Walsh-Wein Urology:
-
Phase II dose-ranging study (Chapple et al., 2004): Evaluated 2.5, 5, 10, 20 mg in 225 patients with urodynamically confirmed detrusor overactivity (DO). Statistically significant reduction in micturition frequency at effective doses.
-
Phase III RCT (Cardozo et al., 2004): 911 patients randomized to solifenacin 5 mg, 10 mg, or placebo for 12 weeks. Both doses significantly reduced micturition frequency, urgency episodes, and incontinence.
-
STAR Trial (Chapple et al., 2005/2007): Head-to-head comparison with tolterodine extended-release over 12 weeks. Solifenacin 5 or 10 mg was non-inferior and in some endpoints superior to tolterodine ER in reducing urgency and incontinence.
-
Cardiovascular safety (Michel et al., 2008): Open-label postmarketing surveillance in real-life clinical conditions - concluded solifenacin was well tolerated with acceptable cardiovascular safety.
Combination Therapy
Solifenacin + Mirabegron (a beta-3 agonist) is a well-studied combination. Three combinations tested in trials:
- Solifenacin 5 mg + Mirabegron 50 mg
- Solifenacin 10 mg + Mirabegron 25 mg
- Solifenacin 10 mg + Mirabegron 50 mg
All three showed significant improvements over solifenacin 5 mg monotherapy and placebo, with no severe adverse events. This combination has a complementary mechanism (antimuscarinic + beta-3 agonist) and is approved as the fixed-dose combination Vibegron/Solifenacin in some markets.
Adverse Effects
Common (anticholinergic class effects):
- Dry mouth (most common)
- Constipation
- Blurred vision
- Urinary retention (especially with pre-existing voiding dysfunction)
- Dry skin/eyes
- Dyspepsia / nausea
Serious / rare:
- QT prolongation - rare but reported; caution with other QT-prolonging drugs (amiodarone, certain fluoroquinolones)
- CNS anticholinergic effects - headache, confusion, hallucinations, somnolence (monitor especially at initiation or dose increase)
- Urinary tract infection
- Severe allergic reactions (angioedema)
Contraindications & Precautions
- Urinary retention (absolute contraindication)
- Gastric retention / uncontrolled narrow-angle glaucoma
- Hypersensitivity to solifenacin
- Caution in: elderly patients (fall/confusion risk), renal/hepatic impairment, patients with prolonged QT or on QT-prolonging agents
- Avoid in patients at risk for anticholinergic CNS toxicity - do not drive or operate heavy machinery until effect is known
Drug Interactions
| Interacting Drug | Effect |
|---|---|
| CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) | Increased solifenacin plasma levels - dose cap at 5 mg |
| Other anticholinergics (diphenhydramine, TCAs) | Additive anticholinergic toxicity |
| QT-prolonging drugs (amiodarone, some fluoroquinolones) | Additive QT prolongation risk |
Summary
Solifenacin is a well-absorbed, once-daily antimuscarinic with modest M3 selectivity, a long half-life (45-68 hours), and extensive CYP3A4 metabolism. It is effective for OAB (reducing urgency, frequency, and incontinence), is non-inferior to tolterodine ER in head-to-head trials, and works synergistically when combined with mirabegron. Its tolerability profile is typical of antimuscarinics - dry mouth and constipation are the most common complaints - with rare but serious QT prolongation and CNS anticholinergic effects requiring monitoring.
- Campbell-Walsh-Wein Urology, block 65, pp. 3527-3530
Alfazosin
Finding Sources
Searching the Web
alfuzosin pharmacology mechanism uses dose side effects alpha blocker BPH
Reading File
Finding Sources
Reading File
Reading File
Here is a comprehensive overview of Alfuzosin drawn from authoritative urology and pharmacology textbooks.
Alfuzosin (Alfuzosin Hydrochloride)
Brand Name: Uroxatral (US), Xatral (Europe)
Drug Class: Selective α1-adrenergic receptor antagonist (alpha-blocker) - uroselective
Pronunciation: al-FUE-zoe-sin
Receptor Pharmacology & Uroselectivity
Alfuzosin is a selective α1-blocker with a unique property: functional/clinical uroselectivity despite lacking in vitro subtype selectivity. This distinction is important:
| Property | Alfuzosin | Tamsulosin / Silodosin |
|---|---|---|
| In vitro subtype selectivity | Blocks α1A AND α1B (non-subtype selective) | Selective for α1A (prostate-specific) |
| Tissue preference | High selectivity ratio for prostate over vascular tissue | Prostate-selective |
| CNS penetration | Poor - low CNS diffusion | Variable |
| Blood pressure effect | Moderate (due to α1B blockade) | Minimal |
The receptor subtypes involved:
- α1A - prostate, bladder neck, prostatic urethra - mediates smooth muscle contraction
- α1B - prostate and vasculature - reduces peripheral vascular resistance when blocked
- α1D - vasculature and bladder
Alfuzosin blocks α1A and α1B, which means it relaxes prostatic smooth muscle effectively but also has mild vasodilatory effects. However, its preferential distribution to urogenital tissue and poor CNS penetration give it a clinically uroselective profile with lower cardiovascular and CNS side effects than older non-selective agents like doxazosin and terazosin.
- Lippincott Illustrated Reviews: Pharmacology, p. 1465
- Campbell-Walsh-Wein Urology, p. 4410
Mechanism of Action
In BPH, α1-adrenoceptor activation in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra causes smooth muscle contraction, contributing to bladder outlet obstruction (BOO) and lower urinary tract symptoms (LUTS).
Alfuzosin competitively blocks postsynaptic α1 receptors in these structures, causing:
- Relaxation of prostatic and urethral smooth muscle
- Reduced bladder outlet resistance
- Improved urine flow rate
- Relief of voiding and storage LUTS
It does not shrink the prostate - it addresses the dynamic (smooth muscle tone) component of BOO, not the static (glandular) component.
Indications
- Primary: Benign prostatic hyperplasia (BPH) / Benign prostatic enlargement (BPE) with LUTS (urinary frequency, urgency, weak stream, hesitancy, incomplete emptying, dribbling)
- Other uses: Ureteral colic / expulsive therapy for distal ureteral stones (off-label)
- Combination therapy: With 5α-reductase inhibitors (e.g., finasteride) for BPH
Dosing
| Formulation | Dose | Frequency | Notes |
|---|---|---|---|
| Immediate-release (IR) | 2.5 mg | 2-3× daily | Older formulation; less used |
| Extended-release (ER) | 10 mg | Once daily | Standard; must be taken with food |
| Sustained-release (SR) | 5 mg | Twice daily | Intermediate formulation |
- No dose titration required for the ER formulation (unlike terazosin/doxazosin)
- Must be taken with food for best absorption and to reduce dizziness risk
- No dose adjustment needed for mild-to-moderate renal impairment; use caution in severe hepatic impairment
Key Clinical Trial Evidence
From Campbell-Walsh-Wein Urology:
-
Jardin et al. (1991): RCT of IR alfuzosin in 518 men with symptomatic BPH. Significant improvement in both storage (irritative) and voiding (obstructive) symptoms. AEs comparable between groups.
-
Alfuzosin, Finasteride and Combination (AFC) Study (Debruyne et al., 1998): 1,051 patients randomized to alfuzosin 5 mg twice daily, finasteride 5 mg, or combination. Alfuzosin produced rapid symptom relief; finasteride reduced prostate volume; combination had additive benefits.
-
Comparative AE data: Indirect comparison across placebo-controlled trials showed alfuzosin and tamsulosin had significantly lower dizziness rates (0-14%) compared to doxazosin and terazosin (0-20%). Alfuzosin dizziness rates: ~5-12%.
Pharmacokinetics
| Parameter | Value |
|---|---|
| Absorption | Well absorbed orally; food increases bioavailability |
| Half-life | ~8-10 hours (ER formulation) |
| Metabolism | Hepatic, via CYP3A4 |
| Peak effect | 1-4 hours post-dose |
| CNS penetration | Poor (pharmacokinetic basis of uroselectivity) |
Adverse Effects
Common:
- Dizziness / lightheadedness (less than non-uroselective agents)
- Headache
- Fatigue / asthenia
- Nasal congestion / rhinitis
- Orthostatic hypotension (less frequent than doxazosin/terazosin; more than tamsulosin)
- GI: nausea, abdominal pain, constipation
Serious / notable:
- Orthostatic hypotension / syncope - especially on first dose; less common with food and ER formulation
- Intraoperative Floppy Iris Syndrome (IFIS) - iris billows and prolapses during cataract surgery; ALL α1-blockers carry this risk. Ophthalmologist must be informed before cataract surgery.
- QT prolongation - rare but reported; caution with other QT-prolonging drugs
- Retrograde ejaculation - less common than tamsulosin/silodosin (low α1A subtype selectivity is protective here)
CNS effects: Lower than older agents due to poor CNS penetration. Drowsiness and somnolence are less common than with doxazosin/terazosin.
Comparison with Other α1-Blockers
| Drug | Subtype selectivity | Uroselective | Dose titration needed | Food effect | Retrograde ejaculation |
|---|---|---|---|---|---|
| Terazosin | α1A + α1B | No | Yes | No | Rare |
| Doxazosin | α1A + α1B | No | Yes | No | Rare |
| Alfuzosin | α1A + α1B | Yes (functional) | No | Yes (needed) | Rare |
| Tamsulosin | α1A (selective) | Yes | No | Yes (needed) | Common (~10-35%) |
| Silodosin | α1A (highly selective) | Yes | No | Yes (needed) | Very common (~20-30%) |
Contraindications & Precautions
- Moderate-to-severe hepatic impairment (reduced metabolism)
- Concomitant use with other α1-blockers
- Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) - can significantly raise alfuzosin plasma levels
- Hypersensitivity to alfuzosin
- Caution: PDE-5 inhibitors (e.g., sildenafil) - additive hypotensive risk
- Pre-existing QT prolongation or concomitant QT-prolonging drugs
- Inform surgeon/ophthalmologist of use before cataract surgery (IFIS risk)
Drug Interactions
| Interacting Drug | Effect |
|---|---|
| CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) | Increased alfuzosin levels - avoid combination |
| PDE-5 inhibitors (sildenafil, tadalafil) | Additive hypotension |
| Other antihypertensives | Enhanced hypotensive effect |
| Other α1-blockers | Additive; avoid |
| QT-prolonging agents | Additive QT prolongation risk |
Summary
Alfuzosin is a uroselective α1-blocker used primarily for BPH-related LUTS. Although it blocks both α1A and α1B receptor subtypes (unlike the subtype-selective tamsulosin/silodosin), its preferential distribution to urogenital tissue and poor CNS penetration give it clinical uroselectivity - high efficacy for voiding symptoms with a lower burden of cardiovascular and CNS side effects than doxazosin or terazosin. The ER 10 mg once-daily formulation requires no dose titration, must be taken with food, and is metabolized via CYP3A4. Retrograde ejaculation is uncommon, making it a preferred choice when preservation of ejaculatory function is a concern.
- Campbell-Walsh-Wein Urology, pp. 4405-4412
- Lippincott Illustrated Reviews: Pharmacology, pp. 1464-1466
This is a shared conversation. Sign in to Orris to start your own chat.